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Abstract
HIV-infection, certain antiretroviral drug classes, especially protease inhibitors (PI), and
obesity are associated with increased ischaemic heart disease (IHD) risk. However, the
effect of PI-free fixed dose combination (FDC) antiretroviral therapy (ART) on hearts
exposed to ischaemia-reperfusion injury (I/R) is unknown, particularly in obesity. This is
becoming relevant as World Health Organisation guidelines recommend a FDC ART con-
taining (non-) nucleoside reverse transcriptase inhibitors (tenofovir (TDF), emtricitabine
(FTC) and efavirenz (EFV)) as first-line HIV treatment. Additionally, obesity rates are rising
in HIV-infected populations, not only in ART-experienced individuals, but also at the time of
ART initiation, which may further increase the risk of IHD. Therefore, we investigated the
effects of PI-free FDC ART in myocardial I/R-exposed hearts from obese rats. Obesity was
induced in male wistar rats via a 16-week high calorie diet. At week 10, treatment with a
FDC ART drug containing TDF/FTC/EFV was initiated. Biometric and metabolic parame-
ters, as well as myocardial functional recovery and infract size (IS), and myocardial signal-
ling proteins following I/R were assessed after 16 weeks. Obese rats presented with
increased body and intraperitoneal fat mass, elevated triglyceride and TBARS levels, whilst
the hearts responded to I/R with impaired functional performance and increased IS. The
FDC ART treatment did not alter biometric and metabolic parameters in obese rats. In a
novel finding, ART protected obese hearts against I/R as shown by improved functional per-
formance and smaller IS vs. untreated obese hearts. Cardioprotection was underscored by
increased myocardial phosphorylated endothelial nitric oxide synthase (eNOS) and reduced
AMP-kinase levels. In conclusion, these results demonstrate for the first time, that 6-weeks
treatment of obese rats with a FDC ART drug specifically containing TDF/FTC/EFV con-
ferred cardioprotection against I/R. The FDC ART-induced cardioprotection was seemingly
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unrelated to metabolic changes, but rather due to direct cardiac mechanisms including the
up-regulation of myocardial eNOS.
1. Introduction
People living with HIV/AIDS are at higher risk of developing ischaemic heart disease and
experiencing a future cardiac event compared to the general population [1–4]. The develop-
ment of HIV-associated cardiac disease appears to be the consequence of viral and host factors,
protease inhibitor (PI)-containing antiretroviral therapy (ART), and numerous other comor-
bidities [2,3,5]. In addition, obesity, a recognised modifiable ischaemic heart disease risk fac-
tor, is increasingly observed in HIV-infected populations, not only as a consequence of ART-
induced reversal of HIV/AIDS associated weight loss [6–9], but interestingly also in HIV-
infected individuals at the time of diagnosis before the initiation of ART [10,11]. These find-
ings suggest that obesity rates in HIV-infected populations are either approaching or already
mirroring those of the general population [7,8,12], which may pose an additional cardiac risk
in such individuals. Although some antiretroviral drugs, most notably PIs, are associated with
the development of cardiac and metabolic abnormalities [13–15], there is a paucity of data on
the cardiac effects of PI-free, fixed dose combination (FDC) ART drugs specifically containing
nucleoside transcriptase inhibitors (NRTI’s) and non-nucleoside transcriptase inhibitors
(NNRTI’s), especially in the context of ischaemia-reperfusion (I/R) injury. Furthermore, the
role of these specific ART combination drugs in I/R exposed hearts from obese subjects is not
well described, particularly in subjects presenting with obesity at the time of ART initiation.
These knowledge gaps are becoming clinically relevant, both in terms of the rising obesity
rates posing potential additional cardiovascular risk, and recent World Health Organisation
(WHO) guidelines that strongly recommend the use of once daily first-line FDC drugs consist-
ing of two NRTI’s: Tenofovir (TDF) plus Lamivudine or Emtricitabine (FTC), and one
NNRTI: Efavirenz (EFV) [16].
To address the above knowledge gaps, the overarching aim of the present study was to
investigate the role of treatment with a specific FDC ART drug containing TDF, FTC and EFV
in I/R exposed hearts from obese male wistar rats. Furthermore, biometric and metabolic
parameters were assessed, and the expression of selected cardiac proteins measured to deter-
mine whether the drug effects in the hearts were due to metabolic changes or direct cardiac
mechanisms. We chose a model of high calorie diet- (HCD) induced obesity, which has previ-
ously been shown in our laboratory to result in poorer outcomes in isolated perfused rat hearts
exposed to I/R injury [17–19]. The total feeding programme was of 16 weeks’ duration, and
ART treatment commenced in week 10 and continued for the final 6 weeks. At week 10, the
weights of the rats receiving the HCD were significantly higher compared to the control ani-
mals, ensuring that the HCD animals had developed obesity at the time of ART initiation. Fur-
thermore, the experimental design ensured that the effects of both obesity and FDC ART
treatment were appropriately controlled for. This was achieved by the age- and time-matched
inclusion of the following groups: untreated HCD-induced obese rats (receiving HCD and
vehicle treatment: controlling for FDC ART), treated lean control rats (receiving standard
chow and FDC ART treatment: controlling for obesity), and untreated lean control rats
(receiving standard chow and vehicle treatment: controlling for obesity and FDC ART).
The main endpoints of the study included standard biometric and metabolic measurements
in the animals, cardiac function and infarct development following I/R injury, and the
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measurement of important cardiac proteins associated with protection or damage. Biometric
measurements (total body mass (TBM), intraperitoneal (IP) fat mass, heart and liver mass)
were performed to characterize the obesity model and to assess the effects of FDC ART treat-
ment on biometric parameters such as body and organ weights. To assess the effects of obesity
and FDC ART treatment on metabolism and oxidative stress, the following parameters were
measured: fasting blood lipids and glucose levels, as well as serum markers of lipid peroxida-
tion (thiobarbituric acid reactive substance (TBARS) and conjugated dienes (CD)). These
measurements additionally assisted in determining whether any of the observed ART-induced
cardiac effects were related to metabolic mechanisms. The susceptibility of the hearts to an I/R
insult was assessed with a well-characterized isolated rat heart perfusion model [20–22]. The
effects of obesity and FDC ART in the hearts were determined by measurements of mechanical
function and infarct size (IS) development. Finally, in order to determine whether obesity and
FDC ART exerted their effects on the hearts via direct cardiac mechanisms, selected proteins,
mainly derived from the ventricles, were measured. These included known cardioprotective
signalling proteins, endothelial nitric oxide synthase (eNOS) and Akt [23–25], the prominent
myocardial regulator of energy production, 5’ adenosine monophosphate-activated protein
kinase (AMPK) [26], nitrotyrosine, a marker of nitrosative stress [27], and p22 phox, a subunit
of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, which is a prominent
source of myocardial reactive oxygen species production [28].
2. Materials and methods
2.1. Animal care
The study was approved by the Research Ethics Committee: Animal Care and Use, University
of Stellenbosch (Protocol number: SU-ACUM13-00025), and complied with the “Guide for
the Care and Use of Laboratory Animals” (US National Institute of Health: Publication 85–23,
revised 1985) and the South African (SA) National Standards for the Care and Use of Animals
for Scientific Purposes (South African Bureau of Standards, SANS 10386, 2008). Animals were
housed in the Central Research Facility (Faculty of Medicine and Health Sciences, University
of Stellenbosch) at 22˚C, 40% humidity, subjected to a 12-hour artificial day/night cycle. All
surgical procedures on animals were performed under full anesthesia and all efforts were made
to minimize suffering.
2.2. Animals and groups
The overarching aims of the study were to determine whether treatment with a specific FDC
ART (containing TDF, FTC and EFV) affects the function and infarct development in hearts
from HCD-induced obese rats following I/R injury, and whether these responses are associated
with changes in biometric and metabolic parameters, as well as cardiac-specific expression of
selected proteins. To investigate these aims, 118 male wistar rats, approximately 8 weeks old,
were randomly assigned to four groups: (i) vehicle treated lean control group (Control;
n = 28), vehicle treated HCD-induced obese group (HCD; n = 28), ART treated lean control
group (Control+ART; n = 28) and ART treated HCD-induced obese group (HCD+ART;
n = 34).
2.3. Diet and feeding programme
Animals in all four groups had ad libitum access to standard rat chow and tap water. The
obese groups additionally received a HCD rich in fat, carbohydrates and sucrose as previously
developed and used in our laboratory [20,29]. The nutrient and energy composition of the
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standard rat chow vs. HCD were as follow (/100 g): total fat 4.8 g vs. 11.5 g; saturated fat 0.9 g
vs. 7.6 g; cholesterol 2.2 mg vs. 13 mg; protein 17.1% vs. 8.3%; carbohydrates 34.6% vs. 42%;
sucrose 5.3% vs. 20.4%; total dietary fiber 26.9 g vs. 9.3 g; and energy 1272 kJ vs. 1354 kJ
[20,29]. The feeding programme was of 16 weeks’ duration. During the feeding programme,
body weights were recorded individually on a weekly basis (every seven days during the morn-
ing) from week 1 to week 16 of the feeding programme. For the purposes of this study, obesity
was defined as a significant increase in the mean TBM of animals receiving the HCD com-
pared to the lean control animals receiving standard rat chow.
2.4. Drug treatment
A commercially available FDC ART drug, Odimune (Cipla, SA), containing TDF (300 mg),
FTC (200 mg) and EFV (600 mg), was used for the study. To assess the effects of the FDC ART
drug in animals that had developed obesity at the time of ART initiation, drug administration
commenced in week 10 of the feeding programme at which time-point the rats receiving the
HCD were significantly heavier than their control counterparts. Tablets were ground to a fine
powder, and the required amounts weighed out according to recommended therapeutic doses
for humans. Due to the increased metabolic rates exhibited by rats, we followed the recom-
mendations of the US Food and Drug Administration according to which the equivalent drug
dose should be ~6 times higher than the human dose [30]. Based on these calculations, rats in
the treatment groups received TDF (25.8 mg/kg/day), FTC (17.4 mg/kg/day) and EFV (51.6
mg/kg/day). The powdered drug was suspended in 1 ml water and administered to each rat
daily via oral gavage during the last six weeks of the 16-week feeding programme. Vehicle con-
trol animals received 1 ml of drug-free water daily via oral gavage in a time-matched fashion.
2.5. Experimental procedures
Following the 16-week experimental programme, animals were anaesthetized by IP sodium
pentobarbitone (160 mg/kg) injection. Upon disappearance of the foot-pinch reflex, the rats
were weighed and the TBM values recorded, after which the animals were sacrificed via a
clamshell thoracotomy and exsanguination.
2.5.1. Biometric measurements. In addition to the TBM measurements, the IP fat tissue
(including epididymal, retroperitoneal and perirenal fat), liver and heart were removed from
each animal and weighed post-euthanasia in a weighing boat using an electronic scale (Rag-
wag, Torunska, Poland).
2.5.2. Metabolic and oxidative stress analyses. A number of rats (n = 5–6 / group) were
randomly sampled for overnight fasting and subsequent biochemical analyses. Fasting blood
glucose levels were determined by analysing a blood droplet obtained from a tail prick (during
deep anaesthesia) with a commercially available glucometer (Gluco Plus, CIPLA DIBCARE,
Bellville, SA). Furthermore, blood that pooled in the thoracic cavity following exsanguination
was collected and serum extracted for subsequent measurement of the total cholesterol (TC),
high-density lipoprotein cholesterol (HDL), triglyceride (TG), CD, and TBARS levels (Cour-
tesy Dr. Dee Blackhurst, Division of Chemical Pathology, University of Cape Town, SA). TC
and TG levels were determined spectrophotometrically (SPECTRA-max Plus 384 and SoftMax
Pro 4.8 microplate data acquisition and analysis software; Labotec Industrial Technologies,
SA) with enzymatic colorimetric kits (LabAssay Cholesterol; LabAssay Triglyceride; Wako
Chemicals, Germany). HDL was also measured via a colorimetric assay, but a dual separation
method was applied as previously described [31]. Finally, CD and TBARS concentrations were
determined by spectrophotometry (SPECTRA-max Plus 384 as above) and calculated using
the appropriate molar extinction coefficients. CD concentrations were calculated by means of
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absorbance (234 nm after appropriate dilution in cyclohexane (Spectrosol) as previously
reported [32,33]. TBARS levels were determined by a method described by Jentzsch et al. [34],
and concentrations determined via absorbance at 532 nm.
2.5.3. Isolated heart perfusions. After excision and removal of excess fat and connective
tissue, hearts were immediately placed in ice-cold Krebs-Henseleit bicarbonate buffer solution
(composition in mM: NaCl 119; NaHCO3 24.9; KCl 4.7, KH2PO4 1.2; MgSO4.7H2O 0.59;
Na2SO4 0.59; CaCl2 1.25; glucose 10). Following this, the hearts were mounted on an ex vivo
isolated heart perfusion system. The hearts were perfused normothermically (36.8 ˚C) with
non-recirculating Krebs-Henseleit bicarbonate buffer, and continuously gassed (95% O2/5%
CO2) through a sintered glass oxygenator (pH 7.4). Temperature was carefully controlled
throughout the experiment by inserting a temperature probe into the left atrium. The aortic
pressure development was obtained through a side branch of the aortic cannula, which was
connected to a Viggo-spectramed pressure transducer. Coronary flow and aortic output were
measured manually. Hearts were subjected to either global or regional I/R, and the protocols
are shown in Fig 1. The global I/R protocol was used to measure myocardial mechanical func-
tion when the whole heart was exposed to zero perfusion, as well as to provide sufficient tissue
to prepare ventricular homogenates for western blot analyses, while the regional I/R protocol
allowed for the simulation of an acute myocardial infarction of the left ventricle and IS deter-
mination, as well as measurement of myocardial mechanical function in the regional I/R
setting.
Pre-ischaemic and post-ischaemic myocardial functional performance was determined by
measuring peak systolic pressure (PSP), coronary flow (CF), aortic output (AO), cardiac out-
put (CO = CF+AO), and total work (Wt) at the end of the 30 min stabilisation period and at
the end of the 20 minutes working heart phase of reperfusion respectively in hearts subjected
to global and regional ischaemia. The Wt performance of these hearts was calculated according
to the formula of Kannengieser and coworkers [35]. Only hearts with an AO of more than 34
ml/min at the end of the stabilisation period were used for Western blotting and IS determina-
tions. Following regional I/R, the silk suture around the LAD was permanently tied and 0.25%
Fig 1. Isolated heart perfusion protocol: (a) Global, and (b) Regional I/R. Global ischaemia was induced by total cessation of perfusion to the myocardium through
closure of both aortic and atrial cannulae for 20 min. Regional ischaemia was induced by ligation of the proximal left anterior descending coronary artery (LAD) with a
silk suture for 35 min resulting in ~67% reduction in coronary flow.
https://doi.org/10.1371/journal.pone.0208537.g001
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Evans blue solution infused into the heart to outline the viable tissues. The IS was determined
by means of tetrazolium staining as described previously [36]. Briefly, the ventricles were fro-
zen, cut into 2 mm thick transverse slices and subsequently stained with 1% triphenyl tetrazo-
lium chloride in phosphate buffer, pH 7.4, for 10 min. The left ventricular area at risk and
infarcted area were measured by means of computerized planimetry (UTHCSA Image Tool
programme, University of Texas Health Science Center at San Antonio, TX, USA). IS was
expressed as a percentage of the area at risk.
2.5.4. Western blot analysis. The expression and activation by phosphorylation of several
proteins involved in important myocardial signalling pathways were measured via Western
blotting protocol routinely used in our laboratory [22,36,37]. To assess proteins under baseline
conditions, the ventricles of the hearts from the fasted animals (allocated for the biochemical
analyses) were freeze-clamped post-euthanasia and stored at -80˚C. These hearts were not des-
tined for perfusion experiments, hence providing an opportunity to explore baseline protein
status. In a second set of western blot analyses, signalling proteins were assessed in hearts that
had been exposed to 20 min global ischaemia and freeze-clamped after 60 min reperfusion.
Antibodies: The following antibodies were purchased from Cell Signaling Technologies Inc.
(Beverly, Massachusetts, USA): anti-eNOS (catalogue number: ]9572), anti-phospho-eNOS
(Ser1177; catalogue number: ]9571), anti-Akt (PKB/Akt; catalogue number: ]9272), anti-phos-
pho-Akt (Ser473; catalogue number: ]4060), anti-AMPK (catalogue number: ]2532), anti-phos-
pho-AMPK (Thr172; catalogue number: ]2535), and anti- β-tubulin (catalogue number: ]2146).
The following antibodies were purchased from Santa Cruz Biotechnologies Inc. (Santa Cruz, Cali-
fornia, USA): anti-p22-phox (FL-195; catalogue number: sc-20781) and anti-nitrotyrosine (PNK;
catalogue number: sc-55256). (For more information on the antibodies see supporting figures.)
Lysate preparation and analyses: For the preparation of lysates, frozen cardiac tissue of
mainly ventricular origin (approximately 30 mg/heart), previously stored in liquid nitrogen,
was mechanically pulverized and fully homogenized for 2 x 5 seconds (Polytron PT10 homog-
enizer, Next Advance, Inc., New York, USA) in 800 μl ice-cold lysis buffer (20 mM Tris/1mM
ethylene glycol tetraacetic acid, pH 7.4; 1 mM ethylenediaminetetraacetic acid; 150 mM NaCl;
1 mM β-glycerophosphate; 1 mM sodium orthovanadate; 2.5 mM sodium pyrohosphate;
50 μg/ml phenylmethylsulfonyl fluoride; 0.1% sodium dodecyl sulphate; 10 μg/ml aprotinin;
10 μg/ml leupeptinin and 1% triton-X100). The protein concentration was determined by the
Bradford method [38]. Lysates were boiled and stored at -80˚ C. For Western blotting, equal
amounts of proteins were separated on a sodium dodecyl sulphate poly-acrylamide gel and
electro transferred to ImmobilonTM-P membranes (Merck Pty Ltd., Darmstadt, Germany).
The membranes were blocked with Tris-buffered saline (TBS) (pH: 7.6); 0.1% Tween-20 and
5% non-fat powdered milk) and incubated overnight in the primary antibodies. Ponceau-
reversible staining or β-tubulin (after stripping the membranes with 2% NaOH for 5 minutes
and re-probing with β-tubulin was used to validate protein transfer and equal loading as mea-
sured by densitometry software and subsequent statistical analysis confirming no significant
differences between groups). For Western blot analyses on baseline hearts the light emitting
from the luminescence was captured on medical x-ray film and the images analysed by densi-
tometry software (UN-SCAN-IT: Silk Scientific Inc., Orem, UT, USA). The Western blot anal-
yses of post-ischaemic hearts were performed by utilizing the Chemidoc MP Imager System
with Image Lab- 5 software (BIO-RAD Inc., USA). The proteins were detected by covering the
membranes with enhanced chemiluminescence detection reagent (ECL). Values were obtained
and normalized to the mean of the untreated control group. All chemicals used in the Western
blot analyses were obtained from Merck Chemical Co (Cape Town, SA). Horseradish peroxi-
dase (secondary antibody), ECL and hyperfilm were acquired from Amersham, Life Sciences
(Buckinghamshire, UK).
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2.6. Statistical analysis
Weekly TBM during the feeding programme was expressed in gram and statistically analysed
by means of a two-way analysis of variance (ANOVA) followed by a Bonferroni multiple com-
parison. Final TBM and biometric parameters, as well as metabolic and oxidative stress param-
eters were analysed via one-way-ANOVA (with Bonferroni multiple comparison). To
elucidate the exclusive effect of the diet or ART treatment, independent of the other variables,
a student’s t-test was used from time to time. IS was expressed as percentage of the area at risk
and analysed by means of a one-way-ANOVA (with Bonferroni multiple comparison). West-
ern blot data are expressed as–fold change or % change compared to control for increases and
decreases respectively and statistically analyzed by means of a 1-way ANOVA, followed by
Tukey’s multiple comparison. All data were analyzed with GraphPad Prism Version 7 (Graph-
Pad Software, USA). Values are expressed as mean ± standard error of the mean (SEM). Statis-
tical significance was set at a p-value< 0.05.
3. Results
When reporting the results, the experimental groups will be referred to as follows: “Control”:
lean control animals receiving standard rat chow and vehicle treatment; “Control+ART”: lean
control animals receiving standard rat chow and FDC ART treatment; “HCD”: obese animals
receiving standard rat chow + HCD and vehicle treatment; and “HCD+ART”: obese animals
receiving standard rat chow + HCD and FDC ART treatment.
3.1. The effects of the HCD and ART on biometric, metabolic and oxidative
stress parameters
The weekly TBM data are shown in Fig 2. At the end of the 16-week feeding programme, the
HCD and HCD+ART rats were ~9.9% and ~10% heavier compared to their respective lean
controls; however, ART did not affect body mass measurements in either the control of HCD
animals (Fig 2 and Table 1).
In addition to the increased TBM, the HCD-induced obese rat model was further character-
ized by increased % IP fat mass (expressed as absolute IP fat mass / TBM %), as well as
increased serum TG and TBARS levels at the end of the 16-week feeding programme com-
pared to lean control animals (Table 1). In the HCD-induced obese rats, treatment with the
ART drug resulted in increased % liver mass compared to untreated obese rats; furthermore,
ART was associated with reduced serum TC and increased TG levels compared to Control
+ART rats, and with reduced CD levels compared to untreated HCD rats (Table 1). In control
animals, treatment with the ART drug had no effect on any of the biometric parameters, but
did result in increased TBARS levels compared to untreated control (Table 1). Neither HCD-
induced obesity nor ART treatment exerted any effects on fasting serum glucose or HDL
levels.
3.2. The response of hearts to I/R injury: Functional performance and
infarct size
3.2.1. Functional performance. There were no differences in any of the pre-I/R func-
tional performance parameters between the groups, suggesting that baseline function (follow-
ing 30 minutes of stabilisation on the perfusion system) was not affected by any of the
experimental interventions (Table 2).
After exposure to global I/R, hearts from the HCD group showed a significant reduction in
mechanical function with respect to all the measured parameters compared to control hearts.
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Fig 2. Weekly TBM (g) of the rats in each experimental group expressed as the mean TBM / group during the
16-week feeding programme. Control, n = 28; HCD, n = 26; Control+ART, n = 27; HCD+ART, n = 32. ap< 0.05
HCD vs. Control bp< 0.05 HCD+ART vs. Control+ART. Data analysed by 2-way ANOVA, followed by Bonferroni
multiple comparison.
https://doi.org/10.1371/journal.pone.0208537.g002
Table 1. Effects of HCD and ART on biometric, metabolic and oxidative stress parameters.
Control HCD Control+ART HCD+ART
Final TBM (g) (n = 24–27 / group) 397.4 ± 10.53 436.6 ± 10.68a 400.4 ± 9.24 440.7 ± 11.66b
IP Fat Mass (% of TBM)
(n = 24–26 / group)
3.61 ± 0.24 5.83 ± 0.29a 3.09 ± 0.25 5.91 ± 0.34b
Liver Mass (% of TBM)
(n = 24–28 / group)
3.13 ± 0.06 2.93 ± 0.06 3.31 ± 0.08 3.25 ± 0.09c
Heart Mass (% of TBM)
(n = 9–11 /group)
0.40 ± 0.01 0.39 ± 0.01 0.40 ± 0.02 0.39 ± 0.01
Glucose (mmol/L) (n = 5–6 /group) 6.67 ± 0.55 5.82 ± 0.38 5.92 ± 0.57 6.88 ± 0.70
TC (mmol/L) (n = 4–6 /group) 1.18 ± 0.16 1.11 ± 0.07 1.56 ± 0.14 1.07 ± 0.07b
HDL (mmol/L) (n = 5–6 /group) 0.65 ± 0.05 0.73 ± 0.05 0.58 ± 0.05 0.65 ± 0.08
TG (mmol/L) (n = 5–6 /group) 0.20 ± 0.04 0.37 ± 0.06a 0.22 ± 0.02 0.30 ± 0.02b
CD (μmol/L) (n = 5 /group) 119.5 ± 4.74 136.0 ± 7.76a 133.6 ± 15.48 117.9 ± 2.71c
TBARS (μmol/L) (n = 4–6 /group) 20.01 ± 0.71 23.05 ± 0.90a 24.63 ± 1.15a 22.35 ± 2.38
ap< 0.05 vs. Control
bp< 0.05 vs. Control+ART
cp< 0.05 vs. HCD. Data analysed by 1-way ANOVA (followed by Bonferroni multiple comparison) or student’s t-test.
https://doi.org/10.1371/journal.pone.0208537.t001
Combination ART induces cardioprotection in hearts from obese rats
PLOS ONE | https://doi.org/10.1371/journal.pone.0208537 December 5, 2018 8 / 27
In the HCD+ART group, although drug treatment was associated with an improvement in
functional parameters during reperfusion in global I/R exposed hearts vs. untreated HCD
hearts, these changes did not reach significance. Furthermore, ART had no effect on the func-
tional recovery of control hearts during reperfusion after global ischaemia.
When exposed to the regional I/R protocol, functional recovery during reperfusion did not
differ between the HCD and control hearts; whereas in HCD+ART hearts, AO, CO and Wt
were significantly increased compared to the untreated HCD hearts. Interestingly, the
untreated HCD hearts showed the weakest performance in terms of AO (post-regional ischae-
mia) compared to the untreated control and HCD+ART groups. Control+ART hearts showed
an increased CO compared to the untreated control group. The improvement in post-regional
I/R function in the HCD+ART hearts was further underscored by the increase in the number
of hearts that recovered sufficiently to generate AO during reperfusion: from only 14% of the
hearts in the untreated HCD group to 57% in the HCD+ART group. Interestingly, ART treat-
ment also increased the number of AO-generating control hearts from 50% to 83% (Table 2).
3.2.2. Infarct size development. Myocardial infarction was induced in the hearts by liga-
tion of the left anterior descending coronary artery, after which the size of the infarcts was mea-
sured. In hearts from the HCD-induced obese rats, the IS was significantly larger compared to
control hearts. The increase in IS was reversed in HCD hearts treated with ART (Fig 3), further
Table 2. Functional performance of the hearts pre- and post-global and regional I/R.
Control HCD Control+ART HCD+ART
Stabilisation (Pre—I/R)
(n = 11–16)
PSP (mmHg) 105.13 ± 1.57a 100.79 ± 2.40b 101.72 ± 1.69 99.15 ± 2.03c
AO (ml/min) 42.09 ± 1.51d 41.25 ± 1.70b 42.36 ± 1.87e 38.46 ± 1.57f
CO (ml/min) 56.22 ± 1.84d 55.21 ± 2.00b 57.91 ± 1.81e 54.55 ± 2.41f
Wt (mW) 13.24 ± 0.52d 12.35 ± 0.43b 13.25 ± 0.53e 12.24 ± 0.61f
Reperfusion
(Post—I/R)
Global I/R
(n = 4–6)
PSP (mmHg) 83.32 ± 16.79 30.20 ± 19.40g 86.00 ± 8.37 66.83 ± 16.79
AO (ml/min) 16.58 ± 5.34 2.10 ± 2.10g 14.50 ± 5.85 7.17 ± 4.83
CO (ml/min) 27.33 ± 7.00 6.60 ± 4.21g 30.25 ± 9.84 17.92 ± 6.10
Wt (mW) 6.08 ± 1.58 0.94 ± 0.94g 6.37 ± 2.28 3.56 ± 1.41
Regional I/R
(n = 6–10)
PSP (mmHg) 72.10 ± 12.11 63.43 ± 13.62 85.83 ± 3.98 77.00 ± 12.99
AO (ml/min) 6.20 ± 2.86 0.57 ± 0.57 9.17 ± 2.02 6.14 ± 3.00h
CO (ml/min) 14.60 ± 4.58 9.79 ± 0.71 26.25 ± 2.81i 18.50 ± 4.38h
Wt (mW) 2.91 ± 0.99 1.40 ± 0.30 4.82 ± 0.49 3.47 ± 1.02h
Hearts Exhibiting Recovery (Producing
AO) During Reperfusion
Global I/R 5/6 (83%) 1/5 (20%) 3/4 (75%) 2/6 (33%)
Regional I/R 5/10 (50%) 1/7 (14%) 5/6 (83%) 4/7 (57%)
Pre- vs. Post-I/R
ap< 0.05 vs. Control Post-Regional I/R
bp< 0.05 vs. HCD Post-Global and Regional /R
cp< 0.05 vs. HCD+ART Post-Global I/R
dp< 0.05 vs. Control Post-Global and Regional I/R
ep< 0.05 vs. Control+ART Post-Global and Regional I/R
fp< 0.05 vs. HCD+ART Post-Global and Regional I/R
Post-Global I/R:
gp< 0.05 vs. Control
Post-Regional I/R:
hp< 0.05 vs. HCD
ip< 0.05 vs. Control.
Values obtained from each group before ischaemia were not significantly different and were therefore grouped together. Hearts that did not recover during reperfusion
were included in post-I/R statistical analysis. Data analysed by 1-way ANOVA (followed by Bonferroni multiple comparison) or student’s t-test.
https://doi.org/10.1371/journal.pone.0208537.t002
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supporting the beneficial effects exerted by ART on the mechanical function of HCD hearts
exposed to regional ischaemia. No significant inter-group differences were observed in the %
area at risk (Control: 40.16 ± 2.99%; HCD: 31.61 ± 2.29%; Control+ART: 38.91 ± 2.13%; HCD
+ART 39.53 ± 4.80%; p> 0.05), which validated that the LAD ligation procedure was consistent
in all groups and that the differences in IS were not a result of technical reasons.
3.3. Baseline and post-ischaemic expression and activation by
phosphorylation of proteins involved with nitric oxide (NO) production
(eNOS), cardioprotection (PKB/Akt), metabolic regulation (AMPK), and
oxidative stress (nitrotyrosine and p22 phox) in hearts from rats exposed to
HCD and ART
3.3.1. eNOS. Under baseline conditions, total myocardial eNOS protein and phosphory-
lated (activated) eNOS levels were not affected by any of the experimental interventions,
although there was a trend (p = 0.06) for the phosphorylated / total eNOS ratio to increase by
~33% in control+ART hearts vs. untreated control (Fig 4A). Exposure to 20 min global ischae-
mia / 60 min reperfusion resulted in ~5.7-fold increase in phosphorylated eNOS in HCD
+ART hearts vs. untreated control and ~2.3-fold vs. untreated HCD. The I/R protocol also
increased phosphorylated eNOS levels by ~4.6-fold in control+ART vs. untreated control.
Total eNOS expression remained unchanged, and the phosphorylated / total eNOS ratios were
increased in HCD+ART hearts (~7.1-fold vs. untreated control, ~2-fold vs. untreated HCD
and ~1.6-fold vs. control+ART), in HCD hearts (~3.6-fold vs. untreated control), and in con-
trol+ART hearts (~4.5-fold vs. untreated control) (Fig 4B).
3.3.2. PKB / Akt. In baseline hearts, the total and phosphorylated (activated) PKB / Akt
levels were lower in control+ART hearts compared to HCD+ART hearts; however, no differ-
ences were observed in the phosphorylated / total PKB / Akt ratios between any of the groups
(Fig 5A). In hearts exposed to global I/R, phosphorylated PKB / Akt levels were significantly
decreased in the HCD+ART group (~38% vs. untreated control); however total protein levels
and phosphorylated / total ratios remained similar in all groups (Fig 5B).
3.3.3. AMPK. Under baseline conditions, none of the experimental interventions exerted
any significant effects on myocardial AMPK levels (Fig 6A). However, after exposure to global
I/R, phosphorylated AMPK levels were decreased by ~50% in HCD+ART vs. control, ~40% in
HCD vs. control, and ~33% in control+ART vs. control. In addition, total AMPK protein levels
were ~68% decreased in HCD+ART vs. control, ~59% decreased in HCD+ART vs. control
+ART, and ~40% decreased in HCD vs. control,. No changes were observed in the phosphory-
lated / total AMPK ratios (Fig 6B).
3.3.4. Nitrotyrosine. Myocardial nitrotyrosine levels were not affected by any of the
experimental interventions under baseline conditions (Fig 7A). After global ischaemia, no
inter-group differences were observed, except in control+ART hearts, where nitrotyrosine lev-
els trended to be higher compared to untreated control (~47% increase; p = 0.06) (Fig 7B).
3.3.5. p22 phox. Under baseline conditions, p22 phox levels in HCD+ART hearts were
~25% decreased vs. untreated HCD, and ~40% decreased vs. untreated control. Levels were
also ~50% decreased in control+ART hearts vs. control (Fig 8A). After global ischaemia, p22
phox levels were ~2-fold higher in HCD+ART hearts compared to untreated HCD, and
~1.6-fold higher vs. control+ART (Fig 8B).
Fig 3. IS expressed as percentage of the area at risk. Control: 18.26 ± 1.66; HCD: 35.40 ± 4.95; Control+ART: 19.91 ± 1.30; HCD+ART: 19.95 ± 2.70. Control,
n = 8; HCD, n = 7; Control+ART, n = 4; HCD+ART, n = 8. ap< 0.05, bp< 0.05. Data analysed by 1-way ANOVA (followed by Bonferroni multiple comparison).
https://doi.org/10.1371/journal.pone.0208537.g003
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4. Discussion
In the present study, we investigated the cardiac and metabolic effects of a commercially avail-
able FDC ART drug, containing a combination of two NRTI’s (TDF and FTC) and one
NNRTI (EFV), in a rat model of diet-induced obesity. The rationale for the study arises from
the now well recognized increased risk of myocardial infarction in HIV-infected populations,
together with increasing obesity rates that are often observed at the time of HIV diagnosis
before ART initiation [11]. Obesity, a modifiable cardiovascular risk factor, could potentially
pose an additional risk for ischaemic heart disease in HIV-infected individuals. Furthermore,
the specific drug combination under investigation in this study, is one that is strongly recom-
mended by the WHO for first line ART [16]. Combination ART drugs are recommended in
view of the ability of the HI-virus to develop drug resistance against individual drugs used as
mono-therapy. Notably, this FDC ART drug does not contain a PI, which is relatively well
researched, and has previously been shown to be associated with increased myocardial infarc-
tion risk and metabolic derangements [39,40]. On the other hand, the role of the TDF, FTC
and EFV combination drug in hearts from obese subjects, especially in the context of I/R
injury, is not well described, and it is not known whether the susceptibility of the hearts to I/R
injury is affected by the drug. In view of the above knowledge gaps, we investigated the cardiac
and metabolic effects of a recently introduced FDC ART drug (consisting of TDF, FTC and
EFV; commercially available as Odimune) administered once daily to HCD-induced obese
rats for six weeks, comparing the findings with appropriate lean and vehicle treated control
animals.
The main findings of the study are (1) the FDC ART treatment did not alter the obese phe-
notype of the rats in terms of biometric or metabolic variables; however, serum CD levels
(marker of lipid peroxidation) were decreased with ART, (2) HCD-induced obesity resulted in
weaker cardiac function and larger IS in hearts subjected to a simulated myocardial infarction
protocol and I/R injury; in a novel finding, treating the obese rats with the FDC ART protected
their hearts against the ischaemic insult, as evidenced by improved post-I/R functional perfor-
mance and reduced IS, (3) measurements of cardiac proteins revealed that the ART-induced
cardioprotection was associated with increased activation of the cardioprotective eNOS pro-
tein and reduced activation of AMPK, an important regulatory protein of energy production
in the heart. (4) overall, the protection conferred by the FDC ART in the obese hearts against
I/R injury appeared to be associated with direct cardiac mechanisms, most notably the up-reg-
ulation of eNOS, rather than an improvement in the biometric and metabolic profile of the
animals.
4.1. The biometric and metabolic effects of the FDC ART drug treatment
At the end of the 16-week feeding programme, the HCD-induced obesity phenotype was char-
acterised by increased TBM, increased visceral fat mass, as well as increased serum TG, CD
and TBARS levels compared to control rats (Table 1), as shown by others using similar HCD’s
[36,41–43]. Fasting blood glucose levels were not affected, suggesting that insulin resistance
and diabetes were not induced by the feeding programme, as previously shown by others
using similar diets [44,45]. Our data show that body and IP fat weights were not altered by the
FDC ART treatment in either the obese or control animals. However, ART-treated obese rats
did present with increased liver: body mass ratios (Table 1), suggesting that ART may have
Fig 4. Western blot measurements of eNOS protein expression and phosphorylation at (a) baseline conditions,
and (b) post-global I/R conditions. n = 3–4 /group. ap< 0.05 vs. Control, bp< 0.05 vs. Control+ART, cp< 0.05 vs.
HCD. Data analysed by 1-way ANOVA (followed by Tukey’s multiple comparison).
https://doi.org/10.1371/journal.pone.0208537.g004
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induced hepatomegaly in the obese animals. NRTIs and PIs are implicated in the pathogenesis
of HIV-related lipodystrophy, and NRTIs in particular are associated with cardiac and hepatic
lipid accumulation, and hepatomegaly [46]. Overall, our biometric data suggest that the FDC
ART regimen did not induce lipodystrophy-like effects in either the control or HCD-induced
obese rats, with the exception of modestly increased liver weights in the ART exposed obese
group.
In our hands, the elevated TG levels observed in the untreated obese animals remained high
in the FDC ART exposed animals, whereas the ART-exposed obese rats had lower TC levels
compared to ART-treated control rats, suggesting that the drug exerted favourable effects on
TC levels in the presence of obesity (Table 1). In the non-obese control rats, the TC, HDL and
TG levels were unaffected by the FDC ART. We are not aware of previous studies investigating
the effects of this FDC ART on blood lipids in the context of obesity. In the non-obese setting,
ART has previously been associated with dyslipidaemia [47–49] and hypercholesterolemia [50–
52] with PIs seemingly the main culprits. Mono-therapy with TDF, one of the components of
the current study’s combination drug, has previously been shown to exert favourable effects on
blood lipids in a clinical study [53]; whereas another FDC ART component, EFV, has been asso-
ciated with dyslipidaemia [54]. In the present study, treatment with the FDC ART did not affect
fasting glucose levels in either control or HCD rats. As far as we are aware, no data are available
on the effects of this specific FDC drug on blood glucose levels in obese animals. However, in
the non-obese context, ART has been associated with impaired glucose homeostasis [55,56]. On
the other hand, a study in ART exposed HIV-infected participants failed to demonstrate
changes in fasting blood glucose, despite observing a positive association between ART and obe-
sity [57]. In summary, the FDC ART did not significantly alter the metabolic profile of the
obese rats, with the exception of reduced TC levels when compared to treated control rats.
Serum markers of lipid peroxidation were differentially affected by treatment with the FDC
ART drug in the control and obese groups. TBARS levels were increased in ART-exposed con-
trol animals; whereas CD levels were lower in ART-exposed obese animals compared to the
control+ART group (Table 1), suggesting that the combination drug exerted favourable effects
on CD levels in the obese, but not in the lean, animals. More studies are required to investigate
this phenomenon. Despite the lack of studies investigating oxidative stress in the context of
FDC ART and obesity, it is known that HIV-infected ART exposed individuals are at risk of
developing systemic oxidative stress [40], due to the failure of anti-oxidant systems and/or
increased ROS production [58]. Mono-therapy with EFV, one of the components of the cur-
rent study’s FDC ART drug, has previously been shown to result in higher levels of systemic
oxidative stress markers compared to a PI-based regimen in HIV-infected participants [59]; in
contrast, another study showed that NNRTI-treated patients had lower oxidative stress levels
[60]. Overall, the experimental design of the current study did not include groups treated with
the individual components of the FDC ART drug, which precludes comprehensive compara-
tive insights, but it appears that the combination drug may have a favourable effect in the
obese rats.
4.2. The cardiac effects of the FDC ART drug treatment
HIV-associated cardiomyopathy (particularly common in the pre-highly active ART
(HAART) era) still persists today, albeit at lower rates [61]. For example, in a study conducted
Fig 5. Western blot measurements of PKB / Akt protein expression and phosphorylation at (a) baseline conditions,
and (b) post-global I/R conditions. n = 3–4 /group. ap< 0.05 vs. Control+ART. Data analysed by 1-way ANOVA
(followed by Tukey’s multiple comparison).
https://doi.org/10.1371/journal.pone.0208537.g005
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in 2011, ART exposed persons showed an unexpectedly high prevalence of left ventricular dys-
function and hypertrophy; in addition, it was shown that cardiomyopathy was independently
associated with increased body weight and the use of an NRTI [62]. In our hands, using an ex
vivo working rat heart model, the FDC ART drug did not affect any of the baseline myocardial
function parameters in either control or HCD rat hearts, thus excluding the development of
myocardial dysfunction/cardiomyopathy (Table 2). We are not aware of any previous animal
studies that investigated the effects of this particular FDC ART drug on cardiac function.
Although baseline myocardial functional performance was not affected, HCD-induced obe-
sity was associated with reduced myocardial functional performance and increased infarct
development after exposure to I/R injury (Table 2; Fig 3), as previously shown by others [63–
65]. These findings confirm that the diet-induced obesity model of the current study negatively
impacted on the hearts’ susceptibility to a simulated myocardial infarction procedure and I/R
protocol. Our results furthermore show that the FDC ART treatment was overall cardioprotec-
tive. Hearts from ART-treated control rats exposed to regional ischaemia generated higher car-
diac outputs during reperfusion vs. untreated control hearts. The improved post-ischaemic
function was even more evident in the hearts from the ART-treated obese rats, showing signifi-
cant improvements in AO, CO and Wt (Table 2). Limited data are available on the effects of
NRTIs and NNRTIs in hearts exposed to I/R injury. As far as we are aware, no data are avail-
able on pre- and post-ischaemic cardiac functional performance in the context of ART in gen-
eral, and the FDC ART drug used in the present study in particular, thus rendering our data
novel. The effects of treatment with the FDC ART drug on infarct development were also
determined following a regional I/R procedure that involved ligation of the left anterior
descending coronary artery. Results showed that the infarcts were significantly smaller, which
underscores the improved functional performance observed in the FDC ART exposed HCD
hearts (Fig 3). These findings are novel, and provide evidence that the particular FDC ART
drug used in the current study, reduces the susceptibility of hearts from obese rats to myocar-
dial infarction and I/R injury. While clinical evidence is relatively conclusive regarding the
myocardial infarction risk of PIs, more data are required on the effects of NRTIs and NNRTIs
[66]. Interestingly, a large cohort study reported that exposure to two of the components of the
FDC drug used in the present study, TDF and EFV, were not associated with increased risk of
myocardial infarction compared to the PI, lopinavir-ritonavir [3].
To gain further information on the putative direct cardiac mechanisms of the FDC ART
drug, the expression and activation of several cardiac proteins were measured. Significant
increases were observed in absolute phosphorylated eNOS levels and phosphorylated / total
eNOS ratios in FDC ART-treated control and obese rat hearts subjected to I/R (Fig 4). In view
of the known cardioprotective properties of cardiac eNOS-NO [67], we postulate that the
strong post-ischaemia increases in eNOS activation may, at least in part, be a candidate mecha-
nism underlying the ART-associated cardioprotection observed in both functional recovery
and IS development. We are not aware of any other studies that investigated myocardial eNOS
in the context of ART, and certainly not in hearts exposed to I/R. Future studies exploring
ART-induced eNOS activation patterns and the effects of manipulation (genetic or pharmaco-
logical) of the eNOS pathway may shed more light as to the exact role of eNOS in myocardial
protection by this particular FDC ART drug.
Although ART resulted in higher baseline levels of phosphorylated PKB/Akt in HCD hearts
compared to control+ART hearts, there were no differences in the phosphorylated/total PKB/
Fig 6. Western blot measurements of AMPK protein expression and phosphorylation at (a) baseline conditions,
and (b) post-global I/R conditions. n = 3–4 /group. ap< 0.05 vs. Control, bp< 0.05 vs. Control+ART. Data analysed by
1-way ANOVA (followed by Tukey’s multiple comparison).
https://doi.org/10.1371/journal.pone.0208537.g006
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Akt ratios (Fig 5). In the post-I/R scenario, phosphorylated PKB/Akt levels were significantly
decreased in the FDC ART exposed obese hearts compared to untreated control; however, the
significance was lost when data were expressed as ratios of total protein. The PKB/Akt pathway
has previously been shown to be targeted by ART; for example, HAART-treated HIV-infected
participants with signs of lipodystrophy showed impaired insulin signalling in skeletal muscle
at the level of PKB/Akt [68]. We are not aware of any animal studies investigating myocardial
PKB/Akt in the context of I/R injury in ART and obesity. It is therefore difficult to place our
results in context; however, overall the rather modest changes observed in PKB/Akt following
FDC ART-treatment suggest that this pro-survival protein is an unlikely candidate mechanism
of the protection observed in the post-I/R HCD-induced obese hearts. In the present study,
treatment with the FDC ART drug did not affect baseline myocardial AMPK levels. However,
in the post-I/R setting, total and phosphorylated AMPK levels were significantly lower in
ART-treated control and obese groups, which coincided with the cardioprotection elicited by
the treatment, suggesting a lesser degree of metabolic stress in these hearts (Fig 6), in view of
AMPK’s role as a major regulator of energy production [26].
In baseline hearts, nitrotyrosine levels remained unchanged in all groups; however, p22
phox levels were lower in the ART-treated control and HCD groups, suggesting that, under
baseline conditions, the FDC ART may have conferred inhibition of myocardial NADPH-oxi-
dase activity and hence possibly reduced reactive oxygen species (ROS) levels (Figs 7 and 8).
In contrast to our findings with the FDC ART drug, a previous study in rats exposed to mono-
therapy with a single NRTI, showed increased myocardial NADPH-oxidase activity [69].
Increased myocardial nitrotyrosine levels were shown in NRTI / PI exposed transgenic HIV
mice (18 weeks treatment), which was associated with cardiac dysfunction; however these
observations may be the result of synergism between HIV-infection and ART, and the pres-
ence of a PI may have played a role [70]. After exposure to I/R, ART-treated control hearts
showed a trend towards increased nitrosative stress (increased nitrotyrosine expression;
p = 0.06); however, no changes were observed in the ART exposed obese group. Furthermore,
I/R injury elicited increases in p22 phox levels in hearts from ART-treated obese rats, suggest-
ing that the I/R insult induced an up-regulation of NADPH-oxidase and possibly increased
superoxide generation. However, the magnitude of the ART-induced increases in p22 phox
levels was seemingly insufficient to result in poorer functional performance or infarct
development.
5. Conclusion
We have shown that a TDF/FTC/EFV fixed-dose combination ART regimen of 6 weeks’ dura-
tion in diet-induced obese rats exerted predominantly favourable effects on metabolic and car-
diac endpoints. These findings are novel, and suggest that, in our hands, this particular
antiretroviral drug combination does not induce harmful cardiometabolic effects as seen with
other ART classes such as PIs. The HCD-induced obese rats particularly benefited from the
FDC ART treatment, particularly in terms of their hearts’ responses to simulated myocardial
infarction and I/R injury. In a novel finding, the FDC ART drug was associated with signifi-
cant cardioprotection in I/R exposed hearts from the obese rats, which was underscored by
strong up-regulation of myocardial phospho-activated eNOS levels. The findings suggest that
the cardioprotection may have been a result of direct cardiac mechanisms rather than an
improved metabolic status. Our results raise the possibility that this combination drug may be
Fig 7. Western blot measurements of nytrotyrosine protein expression at (a) baseline conditions, and (b) post-global I/R
conditions. n = 3–4 /group. Data analysed by 1-way ANOVA (followed by Tukey’s multiple comparison).
https://doi.org/10.1371/journal.pone.0208537.g007
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considered as a possible treatment option in obese HIV-infected individuals with a high risk of
developing ischaemic heart disease; however, more research is necessary to ascertain whether
the favourable effects are also observed in the presence of HIV-infection.
6. Limitations of the study
The study has several shortcomings. Our animal model was HIV-free, which precluded an
opportunity to measure the drug effects in the presence of HIV-infection and an inflammatory
milieu. On the other hand, using a HIV-free model allowed the researchers to focus on the
drug effects per se. Future studies in for example murine HIV models or transgenic AIDS mice
may provide clarity on how the ART drug affects the cardiometabolic endpoints in the pres-
ence of possible viral actions. It may be argued that the ART treatment period of 6 weeks was
too short; indeed, a longer treatment period may have provided more explicit findings. We
also did not investigate ex vivo effects of the drugs administered directly to the hearts during
the perfusion protocol. The advantages of such supplementary studies would be to confirm
that the cardioprotective effects were direct drug effects and not related to other unknown cir-
culating factors. Finally, this study did not include experimental groups that received the indi-
vidual components of the combination drug separately. Although this would have added
considerably to the complexity of the study with three extra groups of rats, it may have pro-
vided clues as to whether the findings were a result of combined effects, or due to the actions
of one or more of the individual components.
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